CTLA4 and neoplasm: An inhibition of these molecules, exploiting immune checkpoint inhibitors (CPIs) such as the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab, causes an enhancement of tumor directed CD 8+ T cells, which can result in durable remission of different tumor types (6).